KEY TAKEAWAYS
- The study aimed to explore WFDC2’s role in LUAD prognosis and its expression, survival impact, and potential functions.
- The results showed that WFDC2 is associated with clinical benefits of immune checkpoint inhibitors in LUAD.
The prognosis for lung adenocarcinoma (LUAD), the most prevalent type of lung cancer, remains poor. The function and mechanism of whey acidic protein four-disulfide core domain 2 (WFDC2) in LUAD are not well understood.
Bo Min and the team aimed to examine WFDC2’s expression in LUAD vs. normal tissues, its impact on overall survival, and its potential roles.
Researchers used online databases to compare WFDC2 expression in LUAD and normal tissues, analyze its relationship with overall survival, and investigate its potential roles.
The results showed that WFDC2 protein and mRNA expression levels were significantly higher in LUAD tissue compared to normal tissue. High WFDC2 mRNA expression was associated with better overall survival and correlated with TP53 mutation status. The biological function of WFDC2 was linked to the cell cycle, with low WFDC2 mRNA expression associated with elevated tumor mutational burden and neoantigen levels.
Additionally, a negative relationship was observed between WFDC2 and immune gene expression, and high WFDC2 mRNA expression was found in patients with LUAD who had low programmed cell death 1 mRNA expression.
The study found that WFDC2 is associated with clinical benefits of immune checkpoint inhibitors in individuals with LUAD.
No funding information was recieved.
Source: https://pubmed.ncbi.nlm.nih.gov/39068532/
Min B, Wang Y. (2024). “WFDC2 is a potential prognostic and immunotherapy biomarker in lung adenocarcinoma.” J Int Med Res. 2024 Jul;52(7):3000605241258893. doi: 10.1177/03000605241258893. PMID: 39068532.
